KR20130072446A - Novel granule formulation with improved solubility - Google Patents

Abstract

PURPOSE: A novel rapid dissolving granule formulation is provided to ensure quick dissolution in oral cavity, to completely remove foreign materials and remnants, and to remarkably improve administration convenience. CONSTITUTION: A rapid dissolving granule formulation contains a rapid dissolving carrier which is selected from the group consisting of sugar and sugar alcohol, and an active ingredient. The rapid dissolving granule formulation is quickly dissolved in oral cavity. A method for manufacturing the granule formulation comprises the steps of: mixing the rapid dissolving carrier and the active ingredient; dissolving a pharmaceutically acceptable binder in a purified water solvent and preparing a binding solution; spraying the binding solution to the mixture of the rapid dissolving carrier and the active ingredient; and mixing a pharmaceutically acceptable additive.

Description

Novel GRANULE FORMULATION WITH IMPROVED SOLUBILITY with Improved Solubility

The present invention relates to a fast dissolving granule form which dissolves rapidly in the oral cavity. Specifically, the present invention relates to a quick-dissolving granule formulation, characterized in that it dissolves rapidly within 20 seconds in the oral cavity during oral administration and has no foreign matter and residual feeling.

More specifically, the present invention relates to a novel fast dissolving granule form obtained by assembling an active ingredient and a fast dissolving carrier that satisfies specific conditions, and promotes dissolution and absorption of the active ingredient, and foreign body feeling and residue in the oral cavity. A novel fast dissolving granule formulation wherein persimmons have been removed and given a refreshing feel.

The most preferred dosage form as an orally administered pharmaceutical formulation is a tablet or capsule, but formulations that disintegrate and / or dissolve rapidly in the oral cavity may be contemplated if the patient is in need of swallowing or needs to be taken without water. . In this case, generally, tablets which disintegrate rapidly in the oral cavity (oral disintegrating tablets, orally disintegrating tablets) or films which dissolve rapidly in the oral cavity (intraoral strip formulations, oral strip technology) are used. However, ODT generally takes at least 30 seconds to completely disintegrate and dissolve in the oral cavity. In particular, ODT may be severely felt in the oral cavity until disintegration is completed. Although it may be possible, it did not significantly increase the ease of taking patients, and there was a problem in that, if the active ingredient had a bitter taste, a separate high-tech concealment technology had to be applied. It is a formulation prepared by mounting components on a film-like strip, which has been used as an oral cleaner, but is basically loaded into a formulation. The amount of the active ingredient is limited, and since the polymer forming the film is sticky, there is discomfort caused by foreign matter and residues in the oral cavity, causing inconvenience to the patient.

On the other hand, with respect to the granules to be administered orally, there is an example in which the herbal extracts are granules, but since they are not the formulations that dissolve immediately in the oral cavity immediately after administration, they must be taken with water, It has been considered a formulation that is far from enhancing patient convenience. In addition, the existing granules have been considered to be suitable for use in mixing with beverages or taken with foods, and very few have been considered as an independent alternative oral alternative to tablets or capsules. In the art, it was common to see granules as intermediates for filling tablets or intermediates for filling capsules. Therefore, it is difficult to find an example of increasing the ease of taking or improving the body dynamics of the active ingredient by using granules as an independent dosage form.

For example, U.S. Patent Application Publication No. US2011 / 0027377 discloses a granule formulation in which the solubility is increased by granulating a poorly soluble drug belonging to class II or class IV by BCS, wherein the above formulation has a maltodextrin and a specific molecular weight. After mixing together with the active ingredient using a polyethylene glycol having, and extruded by a screw extruder (screw extruder) to granulate, the granule size reaches 100 to 2500㎛, which is dissolved in water and administered to animals or used It is difficult to say that the formulation of granules as an independent formulation is difficult to disclose, as related to the manufacture of tablets by tableting (tableting granules, etc.) or to be used in capsules. There is nothing.

US 2011/0117193 discloses a formulation of granulated antiretroviral agents for the treatment of children exposed to HIV / AIDS. Herein, a rapidly dissolving granule form is disclosed. Granules are prepared using saccharin as a sweetening agent and LUDIFLASH, croscarmellose sodium and Kollidon as a disintegrant, but the final dosage form is By describing that granules can be mixed with water and administered as a suspension, it does not disclose granule formulations that can be taken without water.

Korean Laid-Open Patent Publication No. 10-2007-0062978 discloses paracetamol, NSAID and sugar alcohol-containing granules prepared by melt extrusion, and includes alcohol, paracetamol and NSAID salts with other excipients which may optionally be present in the granular component. After drying together, the mixture is heated to a temperature of 100-165 ° C. in the extruder to completely melt the sugar alcohol, thereby mixing the molten sugar alcohol with unmelted NSAID salts, paracetamol and other optional excipients, and melting The granulated mass is poured onto a cooled stainless steel tray or cooled movable belt at 10 ° C., cooled, and then the solidified molten mixture is milled to prepare granules, but here too, the use of granules as an intermediate for preparing tablets. It only discloses the technical idea of making the granule itself as a final dosage form, In addition, since the process of melting the sugar alcohol to a high temperature and mixing it with the active ingredients, and then cooling it again, a special consideration for the high manufacturing cost and equipment was needed.

Korean Patent Laid-Open Publication No. 10-2009-0086469 discloses a powder formulation for a published cyclovir, and the formulation discloses a powder formulation including a published cyclovir, povidone, fumaric acid, benzoate sodium, saccharin, and mannitol. This formulation is also based on the premise of administration in admixture with a separate solution, and thus the final dosage form is a liquid rather than a granule.

In addition, U.S. Patent No. 5169643 discloses a granule formulation containing thiol carbamate, and U.S. Patent No. 5532209 discloses a granule formulation containing propanyl, but these are for pharmaceuticals administered to humans. No consideration was given to rapid dissolution or ease of taking.

From the foregoing prior art, it can be seen that there is no attempt in the art to improve the convenience of taking the granules as a final dosage form, and in particular, it dissolves rapidly in the oral cavity and at the same time in the oral cavity. It is thought that the granule formulation which removes a foreign material feeling and a residual feeling and gives a refreshing feeling has not been examined especially.

United States Patent Application Publication No. US2011 / 0117193 United States Patent Application Publication No. US2011 / 0027377 Korean Patent Publication No. 10-2007-0062978 Korean Patent Publication No. 10-2009-0086469

The present invention is to solve the problem to provide a pharmaceutical formulation in the form of a quick-dissolving granules that dissolve quickly in the oral cavity, can be taken without water and the final dosage form is in the form of granules. Specifically, the present invention is to solve the problem to provide a novel fast-soluble granule formulation that dissolves quickly within 20 seconds in the mouth during oral administration, there is no foreign body and no residual feeling, and is given a refreshing feeling. Furthermore, the present invention is a novel quick-dissolving granule form obtained by assembling an active ingredient and a saccharide satisfying a specific condition, which facilitates dissolution and absorption of the active ingredient and has an advantageous body dynamics according to the active ingredient. It is an object of the present invention to provide a novel fast dissolving granule formulation in which foreign matter and residual feeling are removed and a refreshing feeling is provided.

To this end, the present invention provides the following solutions.

Obtained by assembling the fast-carrier and the active ingredient selected from the group consisting of sugars and sugar alcohols, granules are provided which are rapidly dissolved in the oral cavity during oral administration.

In addition, in the granules, the granules are provided in granules, characterized in that dissolved within 20 seconds in the oral cavity.

In addition, in the granules, the sugar and sugar alcohol are xylitol, mannitol, isomalt, sorbitol, maltitol, purified white sugar, lactose, inositol, erythritol, fructose, trehalose, ribitol, arabitol, galactitol, lactitol And maltotritol and mixtures thereof.

In addition, in the granules, the rapid carrier and the active ingredient are provided in the granules, characterized in that contained in an amount of 40% to 99.995% and 0.005% to 60% by weight of the total formulation weight, respectively. do.

In addition, in the granule formulation, the formulation is a final dosage form, there is provided a granule formulation, characterized in that there is no foreign matter and residual feeling even when taken without water.

In addition, there is provided a medicament comprising a single dose of the granules in a packaging for one dose.

Furthermore, in the present invention, as a granule form obtained by assembling the active ingredient and the fast dissolving carrier rapidly dissolved in the oral cavity, a granule formulation is provided which is dissolved within 20 seconds in the oral cavity during oral administration.

In addition, in the granule formulation, the granule formulation is provided with a granule formulation, characterized in that there is no foreign matter and residual feeling even when taken without water.

Further, in the granule formulation, the rapid carrier is provided a granule formulation, characterized in that the rapid carrier meets the following conditions (1), (2) and (3).

(1) Instantaneous solubility is 30mg / ml or more

(2) 5 minutes solubility is 50 mg / ml or more

(3) Instant solubility is not more than 90% of maximum solubility

In addition, in the granules, the rapid carrier is provided with a granules, characterized in that the sugar or sugar alcohol.

In addition, in the granules, the granules are characterized in that the sugar or sugar alcohol has a heat of dissolution of not more than -4.0 dl / g.

In addition, in the granules, the sugar and sugar alcohol are xylitol, mannitol, isomalt, sorbitol, maltitol, purified white sugar, lactose, inositol, erythritol, fructose, trehalose, ribitol, arabitol, galactitol, lactitol And maltotritol and mixtures thereof.

In addition, in the granules, the granules are characterized in that the sugar alcohol is xylitol.

In addition, in the granule formulation, the granule formulation is provided with a granule formulation, characterized in that there is no foreign matter and residual feeling even when taken without water.

In addition, there is provided a medicine, characterized in that the one-time dosage of the granules in the granules form a medicine for one administration in a packaging container.

In addition, the present invention provides a method for producing granules, characterized in that it comprises the following steps as a method for producing granules that are rapidly dissolved in the oral cavity upon oral administration.

(1) mixing an active ingredient and a fast solubilizer selected from sugars and sugar alcohols;

(2) dissolving a pharmaceutically acceptable binder in a solvent to prepare a binder solution;

(3) spraying the binding liquid of step (2) to the mixture of step (1) to form granules; And

(4) mixing the pharmaceutically acceptable additive with the result of step (3) to form a final granule.

or,

(1) dissolving or suspending a pharmaceutically acceptable binder and an active ingredient in a solvent to prepare a binder solution;

(2) spraying the binding solution of step (2) to the fast carrier selected from sugar and sugar alcohol to form granules; And

(3) mixing the pharmaceutically acceptable additives with the result of step (2) to form a final granule.

Further, in the above production method, the quick-carrier is provided with a fast-carrier, which satisfies the following conditions (1), (2) and (3).

(1) Instantaneous solubility is 30mg / ml or more

(2) 5 minutes solubility is 50 mg / ml or more

(3) Instant solubility is not more than 90% of maximum solubility

In the above production method, the solubilizing agent is xylitol, mannitol, isomalt, sorbitol, maltitol, purified sugar, lactose, inositol, erythritol, fructose, trehalose, ribitol, arabitol, galactitol, lactitol and Provided is a manufacturing method, which is selected from the group consisting of maltotritol and mixtures thereof.

In the above production method, the rapid carrier is provided with a granule formulation, characterized in that it has a heat of dissolution of -4.0 dl / g or less.

In addition, in the above production method, the rapid carrier is provided with a production method, characterized in that xylitol.

Finally, in the present invention, there is provided a method of forming granules used in the manufacture of a medicament using sugars or sugar alcohols satisfying the following conditions (1), (2) and (3).

(1) Instantaneous solubility is 30mg / ml or more

(2) 5 minutes solubility is 50 mg / ml or more

(3) Instant solubility is not more than 90% of maximum solubility

The novel fast dissolving granules of the present invention, unlike conventional oral granules, rapidly dissolve in the oral cavity during oral administration, completely eliminating foreign feelings and residual feelings and at the same time refreshing feeling, thereby greatly improving the convenience of taking. . In addition, compared to the ODT or OST formulation, the oral residence time is much shorter, and it is also possible to more advantageously control the pharmacokinetics of the drug. Furthermore, the novel fast-dissolving granules of the present invention have a relatively simple manufacturing process and are greatly advantageous in terms of cost for the effect, and can be applied to various active ingredients, and thus are suitable as a base technology.

In the present specification, the granule is used as a generic term including all powders, fine granules and granules defined in the Korean Pharmacopoeia, and refers to granular formulations of small fine or general particles. As a process for producing granules, a dry method of mixing an active ingredient, an excipient, and a binder to form a slug or a sheet-like substance to granulate, and a wet method of mixing, granulating and drying with a softener by adding a binder solution to a mixture of the active ingredient or an active ingredient and an excipient. In the wet method, a fluidized bed granulation method is used in which a raw material powder is a fluidized bed using airflow, and then sprayed and assembled with a binder solution, which is advantageous in that mixing, granulation, and drying processes are performed in one machine. Do. The method of producing the granules of the present invention is not particularly limited, but it is preferable to use a fluidized bed granulator.

In the present specification, the sense of foreign body refers to a feeling of causing discomfort due to the recognition of the administered medicine as a foreign substance different from a substance which is normally taken by the patient after administration of the medicine in the oral cavity, for example, This may include a feeling of stickiness, such as sand, or irritating feeling on the oral mucosa or tongue, and also a sticky feeling, such as mucus.

In the present specification, the feeling of retention means that even after a considerable time has passed after administration of the dosage form, for example, about 20 seconds after oral administration, the dosage form containing the active ingredient is dissolved and absorbed, The sense of staying in the oral cavity or the sense associated with traces of the dosage form of the formulation, such as not removing the taste or feel of the formulation in the oral cavity, is retained in the oral cavity, which is not enough to cause foreign body feeling but may cause discomfort in some patients. Means. If there is such a residual feeling, it may cause a desire to drink water or beverage additionally, and in this case, the characteristics of the preparation to be taken without water are not exhibited, so it must be considered together with the foreign body for the improvement of the quality of the preparation. It should be an element.

In the present specification, the refreshing feeling refers to a cool and refreshing feeling that is felt in the local area of the mouth and the entire mouth when the dosage form is administered, which is due to the endothermic reaction when the dosage form is dissolved in saliva. It is expressed by the correlation of the heat of dissolution, dissociation energy and rapidity of dissolution rate of the substances constituting the formulation.

In the present specification, "solubility in water" is a concept defined in the present invention in order to determine the pattern of dissolution at the same time when the formulation of the present invention is administered orally, and is rapidly dissolved in 250 ml of purified water at a temperature of 37 ± 0.5 ℃. 20.0 g of sieve was added and the paddle speed was set at 50 rpm, and the solubility (mg number of the dissolved solubilizer per ml, equal to or less) per 1 minute, 3 minutes, 5 minutes, 10 minutes and 15 minutes was obtained. After plotting the solubility at, 3 and 5 minutes, find the linear regression curve according to the least-squares method and extrapolate it to the intercept that meets the y-axis, that is, theoretically, the instantaneous solubility when time approaches zero. it means. Instantaneous solubility is a formulation in which the formulation of the present invention dissolves quickly or simultaneously with oral administration, and thus, the rapid dissolution effect of the formulation according to dissolution behavior including a change in the dissolution rate of the carrier at the microscopic level and It is the concept which the present inventors derived based on the novel knowledge that a foreign material sense and a residual feeling change.

In the present invention, the solubility for 5 minutes means the solubility in 5 minutes when 20.0 g of the fast solution is added to 250 ml of purified water at a temperature of 37 ± 0.5 ° C. and the paddle speed is 50 rpm. Is a formulation that dissolves rapidly at about the same time as oral administration, and is based on the novel knowledge that rapid dissolution effect, foreign body feeling and residual feeling change according to dissolution behavior including the change of dissolution rate of carrier at micro level. Solubility is defined to determine over time parameters to determine the dissolution behavior in the oral cavity of the rapid carrier at the microscopic level along with the instantaneous solubility.

In the present invention, the maximum solubility means the maximum value that can be dissolved when 20.0 g of the fast solution is added to 250 ml of purified water at a temperature of 37 ± 0.5 ° C. and the paddle speed is 50 rpm, that is, 80 mg / ml. . In the present invention, the maximum solubility is defined as the fast dissolving agent of the present invention is a formulation that dissolves at the same time as intraoral administration. Therefore, it is expected that the higher the instantaneous solubility, the higher the solubility. It was found that there is a case that is not good, and accordingly, it is to set the conditions of the fast-soluble carrier that can dissolve in the oral cavity and remove foreign feelings and residual feelings through the correlation between maximum solubility and instantaneous solubility.

In the present invention, the active ingredient means an active ingredient that can be included in the formulation of the present invention. The present invention is an invention characterized by the formulation itself, and since the basic premise that various active ingredients can be included in the present formulation, such active ingredients are not limited. However, examples of the active ingredient that may be included in the present invention include sildenafil, tadalafil, franlukast hydrate, pseudoephedrine hydrochloride, ranitidine hydrochloride, levocetirizine hydrochloride, and the like. Acceptable salts are also included.

In the present invention, the solute carrier is a carrier constituting the present formulation, which dissolves rapidly upon oral administration, has no foreign matter, no residual feeling, and can impart a refreshing feeling. In particular, the rapid-carrier for achieving the effect of the present invention should be instantaneous solubility and 5 minutes solubility of 30 mg / ml and 50 mg / ml or more, respectively, instantaneous solubility is 90% or less of the maximum solubility, It is preferable that it is -4 Kcal / g or less. Such rapid solubilizers are not particularly limited as long as they are rapidly soluble in the oral cavity as a pharmaceutically acceptable carrier and have no foreign body, no residual feeling, and can provide a refreshing feeling. Preferably used. Examples of such solute carriers include, but are not limited to, xylitol, mannitol, isomalt, sorbitol, maltitol, purified white sugar, lactose, inositol, erythritol, fructose, trehalose, ribitol, arabitol, galactitol, lactitol And pharmaceutically acceptable sugars or sugar alcohols and mixtures thereof, such as maltotritol, and any of these sugars or sugar alcohols satisfying the conditions defined in the present invention, based on compatibility with the active ingredient and other pharmaceutical considerations. It can be used without limitation. Hereinafter, the present invention will be described in detail.

The present invention greatly increases the ease of taking by the use of a novel quick-dissolving granules that can take a variety of active ingredients without water, and solves the inconvenience of ODT or OST that was a conventional formulation without water. As described above, the most preferred dosage form as a conventional oral dosage form was a tablet or capsule taken with water, but depending on the type of indication, the interval between administrations and the administration environment, a dosage form that can be easily carried without water can be used. Occasionally required, ODT or OST formulations were commercially available. However, contrary to the expectation that ODT will disintegrate rapidly in the oral cavity, it is necessary to hold tablets in the mouth for a considerable amount of time, and it is impossible to avoid foreign substances during that time, and also after the dissolution in the oral cavity, It is true that many patients take drinks with water or take it with water from the beginning unlike the original intention. Furthermore, since the basic idea of manufacturing ODT tablets is to compress them at low pressure using a rapidly disintegrating excipient, breakage of the tablets often occurs during storage or distribution, which requires a separate packaging for ODT tablets. It was also undesirable in terms of cost-effectiveness. Furthermore, in the case of an ODT containing an active ingredient having a bitter taste, the concentration of the active ingredient in the oral cavity in which the ODT tablet is placed is inevitably increased, so even if the bite-cloaking technique is used, the patient does not feel the bitter taste completely. It is practically difficult to prevent.

On the other hand, in the case of the OST formulation, another representative formulation that can be taken without water, the active ingredient is loaded into a film-like strip formulation using a film-forming polymer, and the dissolution rate is faster than that of the ODT formulation. There is a fundamental limitation on the amount of active ingredient loaded into the formulation, and since the formulation is sensitive to humidity, there is a possibility that the form of the formulation may be greatly distorted or deformed during storage after manufacture. There was. In addition, as with ODT formulations, if the active ingredient has a bitter taste, a separate means of shielding should be taken. Due to the nature of the strip formulation, once the formulation is placed on the tongue, it is maintained until it dissolves in situ. It is understood that the active ingredient continues to dissolve at a specific site in the oral cavity, and finally, the concentration of the active ingredient at the site is concentrated, so that the patient can feel more bitter taste. In addition, since the OST formulation uses a sticky film-forming polymer, when the dose is taken, it feels foreign matter such as stickiness of the mucous substance in the oral cavity, and when it is stuck to the palatal palate, which is not originally intended at the time of administration. Since it is difficult to change, it could not greatly improve the ease of taking.

In the case of conventional granules, most of the granules that have been commercialized until now are mainly taken by dissolving or suspending them in a drink or water, and thus, it is difficult to classify them into preparations that can be taken without water. In the case of granules that are not mixed with water, when taken with water, patients feel severe foreign body residue and residual feeling in the oral cavity.

Accordingly, the present inventors have developed a novel rapid-soluble granule formulation that overcomes all the disadvantages of ODT, OST and conventional granule formulations, and surprisingly, foreign substances and residual feelings are eliminated when using a rapid-carrier that satisfies certain conditions. The present invention has been found to dissolve much faster than the ODT or OST formulation.

That is, the present invention mixes the active ingredient and the solute carrier, wet granulates with a binder solution in which a pharmaceutically acceptable binder is dissolved, or binds or dissolves / suspends the pharmaceutically acceptable binder and active ingredient in the solute carrier. A novel fast dissolving granule formulation wet granulated with liquid is disclosed. The solubilizing agent of the present invention is preferably sugar or sugar alcohol, but is not limited thereto. Specifically, (1) instantaneous solubility is 30 mg / ml or more, (2) 5 minutes solubility is 50 mg / ml or more and ( 3) It is preferable to use sugar or sugar alcohol whose instantaneous solubility is 90% or less of the maximum solubility.

The instantaneous solubility of the present invention was determined by adding 20.0 g of the solute carrier to 250 ml of purified water at a temperature of 37 ± 0.5 ° C. and setting the paddle speed at 50 rpm to determine the solubility at 1, 3, 5, 10 and 15 minutes. After plotting the solubility at 1, 3, and 5 minutes, find the linear regression curve using the least-squares method, extrapolate it, and intercept the intersection with the y-axis, that is, theoretically, when time approaches zero Instantaneous solubility means, solubility in 5 minutes means solubility in 5 minutes, and maximum solubility means the maximum value that the solubilizing agent can dissolve under the same conditions as above.

The present inventors have found that when the instantaneous solubility is 30 mg / ml or more and the 5-minute solubility is 50 mg / ml or more, the granules dissolve rapidly in the oral cavity, and at the same time, foreign substances and residual feelings cannot be felt, resulting in an extremely high dose convenience. When the instant solubility and the 5-minute solubility satisfy the above conditions, when the instant solubility exceeds 90% based on the maximum solubility, the foreign substance and the residual feeling were not good. In particular, in the present invention, the introduction of the concept of instantaneous solubility must simultaneously satisfy two requirements, that the formulation of the present invention must be quickly dissolved and there should be no foreign matter and residual feeling, In other words, it has been found to be related to the change of the dissolution rate at the micro level (i.e., even if the solubility is high, if the dissolution rate at the micro level is slow or the change in the dissolution rate is slow, a foreign object or residual feeling is felt). Therefore, it was introduced according to the necessity of a parameter that simultaneously evaluates the dissolution rate and solubility reflecting the temporal factors at the micro level.

Therefore, even when the same type of carrier is used and the instant solubility and the 5 minute solubility of the present invention are not satisfied, the dissolution rate in the oral cavity may be slow or the dissolution rate in the oral cavity may be high, but there is a foreign body feeling and residual feeling. It should be noted that the effects of the invention cannot be achieved.

Although the specific fast-carrier used in the present invention is not limited, Preferably, sugar or sugar alcohol can be used. Specific examples thereof include pharmaceutically acceptable such as xylitol, mannitol, isomalt, sorbitol, maltitol, refined sugar, lactose, inositol, erythritol, fructose, trehalose, ribitol, arabitol, galactitol, lactitol and maltotritol. Sugars or sugar alcohols and mixtures thereof, and if the instant solubility is 30 mg / ml or more, 5 minutes or more, 50 mg / ml or more and the instant solubility is 90% or less of the maximum solubility, The absence of this can achieve the effects of the present invention. That is, if the instant solubility of the rapid carrier is less than 30 mg / ml, or if the 5-minute solubility is less than 50 mg / ml, or if the instant solubility exceeds 90% of the maximum solubility, it does not dissolve rapidly in the oral cavity. Or a sense of foreign body and / or residual feeling in the oral cavity. On the other hand, although the dissolution rate may change depending on the particle size, particle size distribution or specific surface area, the fast-carrier is, in the present invention, conditions of instant solubility and 5 minutes solubility, without particular limitations related to individual specific surface area or particle size. It should be noted that if it is satisfied, it can be used as a fast carrier. For example, sugar alcohols specially spray-dried to impart porosity have a small particle size, so that the instantaneous solubility is high but the instantaneous solubility exceeds 90% of the maximum solubility. May not be used as a preferred rapid carrier. That is, the conditions related to the instantaneous solubility and 5 minutes solubility of the present invention are different concepts from the specific surface area and particle size of the fast-carrier, and satisfy the conditions of the present invention even if the specific surface area is large or the particle size is small. If not, the effect of the present invention cannot be achieved. Therefore, it should be noted that the specific surface area of the carrier is increased to increase the dissolution rate and that it is clearly distinguished from the use of the fast dissolving carrier that satisfies the conditions of the present invention.

In addition, from the viewpoint of imparting a refreshing feeling, the formulation of the present invention preferably uses a fast dissolving carrier having a heat of dissolution of -4.0 kPa / g or less. For example, in the case of xylitol, -36.6 kPa / g of heat of dissolution Since it is, it is very preferable from a viewpoint of a refreshing feeling.

On the other hand, the solubilization carrier may be included in an amount of 40% by weight to 99.995% by weight of the granule formulation of the present invention, which can be appropriately changed depending on the active ingredient.

The active ingredient which can be included together with the solute carrier of the present invention is not limited. This means that the technical spirit of the present invention is in the formulation itself, and thus, may include various active ingredients. For example, the granule formulation of the present invention may include sildenafil, tadalafil, franlukast hydrate, pseudoephedrine hydrochloride, ranitidine hydrochloride, levocetirizine hydrochloride, or the like, or a pharmaceutically acceptable salt thereof.

In particular, the granules of the present invention, the shorter the expression time of the drug, the more effective the active ingredient, such as erectile dysfunction or migraine headache, such as an active ingredient that should be expressed quickly, anticipated administration is expected, It is desirable for drugs that should be taken urgently when symptoms develop. In other words, in the case of such a drug, it is often necessary to administer urgently in an unexpected situation, and even when there is no water around, it is often necessary to perform rapid administration, so it is possible to take it without water, It is possible to fully enjoy the advantages of the formulation of the present invention.

On the other hand, the active ingredient may be included in an amount of 0.005% to 60% by weight of the granules of the present invention, which can be appropriately changed depending on the content of the active ingredient.

As a method of preparing the formulation of the present invention, the solubilizing agent and the active ingredient are mixed, and separately, a pharmaceutically acceptable binder is dissolved in a solvent to prepare a binding solution, and a mixture of the gastric solubilizing agent and the active ingredient is granulated. And granulated while spraying the gastric binding solution, and then pharmaceutically acceptable excipients such as sweeteners and fragrances may be post-mixed into the granules thus prepared, and put into a wrapping paper to form granules for single administration. . Alternatively, a binder is prepared by mixing / suspending a pharmaceutically acceptable binder and an active ingredient in a solvent, administering the fast solution to a granulator, and granulating while spraying the above binding solution, followed by sweetening to the granules thus prepared, Pharmaceutically acceptable excipients, such as fragrances, may be post-mixed and placed in packaging paper to form granules for single administration. Since the granules for single administration can be administered in one dose per unit, there is no foreign matter and residual feeling, so even when taken without water, no foreign feeling is felt, and there is no residual feeling and gives a refreshing feeling. There is no desire to drink water even after administration.

Granules according to the present invention can be provided in the form of a portable sachet and three-sided packaging (stick), but is not limited to this, such a packaging container can be carried in a wallet anytime and anywhere can be taken immediately. Has the advantage.

In the above production method, a binder commonly used to facilitate the formation of particles during the granulation process may be used. For example, hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), polyvinyl Pharmaceutically acceptable binders and mixtures thereof, such as pyrrolidone (PVP) and hydroxyethyl cellulose, can be used, and can be dissolved in purified water and used in the form of a binder solution. The amount of these binders may be used in amounts of 0.05% to 15% by weight of the total formulation.

In the present invention, one or more flavoring agents may be used pharmaceutically to improve the flavor of the preparation and to increase the compliance. Acceptable flavors include orange, grape, apple, lemon, strawberry, cherry, pineapple, banana, tuttifruit, blueberry, peppermint, cocoa, peach and milk or pharmaceutical Acceptable flavoring agents and mixtures thereof can be used. Their amount may be included in 0.001% to 10% by weight of the total formulation.

In the present invention, one or more sweeteners may be used to enhance the sweetness of the formulation and to increase dose compliance. The sweetener is an important factor in that it is directly related to the dosage convenience in the oral dosage form. In the present invention, since a sugar or a sugar alcohol is used, the fast carrier itself acts as a sweetener, but a natural sweetener and a synthetic sweetener are used as well. You can also use both. Examples of such sweeteners include, but are not limited to, natural sweeteners such as sugars such as sucrose, dextrose, fructose, glucose, liquid glucose and maltose, saccharin, cyclamate and aspartame acesulfame K, sucralose, Pharmaceutically acceptable synthetic sweeteners such as synthetic sweeteners such as alitam and neotam can be used. Sweeteners can be used in amounts of 0.05% to 20% by weight of the total formulation.

The present invention will be described through the following examples. However, the following examples are not intended to limit the scope of the present invention as an exemplary embodiment of the present invention, it should be noted that various modifications may exist within the spirit of the present invention.

Preparation Examples 1 to 33

The large crystals supplied for sugars and sugar alcohols (xylitol, sorbitol, maltitol, mannitol, isomalt, inositol, lactose, refined white sugar, fructose, trehalose, and erythritol) are pulverized to suit the intended use, and then made by apples. Examples 1 to 33 were used. However, if it can be supplied commercially in an appropriate size, it can be used without additional grinding process. Table 1 below shows the D50 values (unit μm) of the fast-carrier prepared in each preparation example.

Manufacturing example ingredient D50 Production Example 1 Xylitol 63.4 Production Example 2 Xylitol 150.6 Production Example 3 Xylitol 370.6 Production Example 4 Sorbitol 96.1 Production Example 5 Sorbitol 254.2 Production Example 6 Sorbitol 751.6 Production Example 7 Maltitol 25.4 Production Example 8 Maltitol 108.1 Production Example 9 Maltitol 235.2 Production Example 10 Mannitol 40.0 Production Example 11 Mannitol 141.5 Production Example 12 Mannitol 381.1 Production Example 13 Isomalt 47.4 Production Example 14 Isomalt 222.3 Production Example 15 Isomalt 390.2 Production Example 16 Inositol 49.2 Production Example 17 Inositol 86.8 Production Example 18 Inositol 273.7 Production Example 19 Lactose 30.7 Production example 20 Lactose 112.0 Production Example 21 Lactose 192.2 Production Example 22 Refined sugar 56.9 Production Example 23 Refined sugar 319.7 Production Example 24 Refined sugar 413.9 Production example 25 Crystalline fructose 144.0 Production Example 26 Crystalline fructose 312.9 Production Example 27 Crystalline fructose 468.9 Production Example 28 Trehalose 129.7 Production Example 29 Trehalose 326.8 Production Example 30 Trehalose 512.0 Production Example 31 Erythritol 85.3 Preparation Example 32 Erythritol 447.8 Production Example 33 Erythritol 648.3

Test Example 1

In order to obtain the instantaneous solubility of the solute carriers prepared in Preparation Examples 1 to 33, 20.0 g of each sample was placed in a weighing dish, and slowly charged into 250 ml of purified water at a paddle speed of 50 rpm at 37 ± 0.5 ° C. Solubility in 1 minute, 3 minutes, 5 minutes, 10 minutes, 15 minutes was carried out under the same conditions as Table 2 and analyzed by the method shown in Table 3. Table 4 shows the solubility for each elution time.

Manufacturing example 1 minute 3 minutes 5 minutes Production Example 1 67 77 77 Production Example 2 51 70 74 Production Example 3 22 34 44 Production Example 4 73 72 76 Production Example 5 54 75 77 Production Example 6 34 54 66 Production Example 7 49 57 61 Production Example 8 47 61 72 Production Example 9 28 41 50 Production Example 10 64 71 73 Production Example 11 74 77 76 Production Example 12 33 45 49 Production Example 13 58 66 71 Production Example 14 56 74 79 Production Example 15 36 46 48 Production Example 16 58 74 80 Production Example 17 40 54 73 Production Example 18 23 47 52 Production Example 19 40 74 76 Production example 20 36 42 51 Production Example 21 29 37 45 Production Example 22 44 52 60 Production Example 23 24 36 46 Production Example 24 23 35 45 Production example 25 47 61 71 Production Example 26 35 44 52 Production Example 27 21 32 40 Production Example 28 57 66 72 Production Example 29 37 49 58 Production Example 30 15 29 39 Production Example 31 44 53 58 Preparation Example 32 13 34 51 Production Example 33 10 22 41

After plotting the solubility 7 degrees at 1 minute, 3 minutes, and 5 minutes shown in Table 4 on the graph, a linear regression curve was calculated according to the least square method, and each y-intercept value was defined as instantaneous solubility. Instantaneous solubility and 5-minute solubility for each preparation example are shown in Table 5 below. Table 5 also shows whether instantaneous solubility of 30 mg / ml or more and 5 minutes of solubility of 50 mg / ml or more, which is the fast-carrier condition of the present invention, is also satisfied.

Example 1

As shown in Table 6, hypromellose and polyvinylpyrrolidone were dissolved in purified water and sprayed onto a mixture of sildenafil free base and Preparation Example 2 using a fluid bed granulator (Fluid Bed Granulator, Glatt, Germany) to obtain granules. . The final granules were prepared by mixing sucralose and peppermint flavor to the prepared granules.

Comparative Example 1

As shown in Table 7, after the sildenafil free base, corn starch, crospovidone, hydroxypropyl cellulose, rudy flash, prosolve, citric hydrate with apple No. 26 (600 ㎛) apples and mixed, colloidal silicon oxide and stearyl Sodium fumarate was appled into No. 30 sieve (500 μm), and then mixed with the mixture to prepare a final mixture. The final mixture was compressed into tablets using a single tablet press (XENA-I, RAON, KOREA).

Comparative Example 2

As shown in Table 8, it was prepared in the same manner as in Comparative Example 1 except that sildenafil citrate was used instead of sildenafil free base.

Examples 2 to 34

Hypromellose and polyvinylpyrrolidone were dissolved in purified water as shown in Tables 9 to 12, respectively, and sprayed onto the mixture of francastate hydrate and Preparation Examples 1 to 33 using a fluid bed granulator (Fluid Bed Granulator, Glatt, Germany). To obtain granules. The final granules were prepared by mixing sucralose and peppermint flavor to the prepared granules.

Examples 35-67

As shown in Tables 13 to 16, hypromellose and polyvinylpyrrolidone are dissolved in purified water and sprayed onto the mixture of pseudoephedrine hydrochloride and Preparation Examples 1 to 33 using a fluid bed granulator (Fluid Bed Granulator, Glatt, Germany), respectively. To obtain granules. The final granules were prepared by mixing sucralose and peppermint flavor to the prepared granules.

Examples 68-100

Hypromellose and polyvinylpyrrolidone are dissolved in purified water as shown in Tables 17 to 20, respectively, and then sprayed onto the mixture of tadalafil and Preparation Examples 1 to 33 using a fluid bed granulator (Fluid Bed Granulator, Glatt, Germany). To obtain granules. The final granules were prepared by mixing sucralose and peppermint flavor to the prepared granules.

Examples 101 to 108

Hypromellose and polyvinylpyrrolidone are dissolved in purified water, as shown in Table 21 below, and lanitidine hydrochloride and Preparation Examples 1, 9, 12, 13, 15, 22 using a fluid bed granulator (Fluid Bed Granulator, Glatt, Germany). , 25, and 27 were respectively sprayed to obtain granules. The final granules were prepared by mixing sucralose and peppermint flavor to the prepared granules.

Examples 109-117

Hypromellose and polyvinylpyrrolidone were dissolved in purified water as shown in Table 22 below, and prepared with levocetirizine hydrochloride using a fluid bed granulator (Fluid Bed Granulator, Glatt, Germany) 4, 7, 10, 18, 19 , 23, 28, 31, and 32 were respectively sprayed on a mixture to obtain granules. The final granules were prepared by mixing sucralose and peppermint flavor to the prepared granules.

Test Example 2

In Example 1, Comparative Example 1 and Comparative Example 2 was carried out a sensory test on the oral dissolution rate, foreign body, bitter taste, residual feeling in six healthy adults. The results were evaluated according to the evaluation criteria of the following Table 23 (sugar and sugar alcohol sensory test evaluation criteria) and are shown in Table 24 (Example sensory test results for each example) and Table 25 (test individual sensory test results).

Test Example 3

Sensory tests on oral dissolution rate, foreign body feeling and residual feeling were carried out on 6 healthy adults with Preparation Examples 1 to 33. The results are shown in Tables 27 to 29 according to the evaluation criteria in Table 26 below.

Example Oral Dissolution Time
(second) Foreign body feeling Residual feeling Example 2 4.7 0.2 A Example 3 7.2 1.3 A Example 4 15.0 3.5 B Example 5 8.2 1.0 A Example 6 8.2 1.8 A Example 7 17.7 4.7 B Example 8 13.3 1.3 A Example 9 16.3 1.8 A Example 10 23.0 4.5 B Example 11 9.3 0.3 A Example 12 15.7 4.0 B Example 13 19.8 2.5 C Example 14 6.0 0.5 A Example 15 11.7 1.8 A Example 16 13.7 2.6 C Example 17 10.0 1.2 A Example 18 15.8 1.7 A Example 19 27.3 4.5 B Example 20 9.0 0.3 A Example 21 12.8 0.8 A Example 22 15.5 3.2 B Example 23 6.8 0.2 A Example 24 9.5 3.2 B Example 25 14.7 4.0 B Example 26 6.0 0.2 A Example 27 8.0 1.2 A Example 28 11.2 3.2 B Example 29 7.5 1.0 A Example 30 12.7 2.0 A Example 31 15.3 3.3 B Example 32 6.8 0.5 A Example 33 11.2 3.3 B Example 34 18.7 3.9 B Example 35 5.0 0.7 A Example 36 7.7 1.5 A Example 37 14.8 3.8 B Example 38 8.2 1.0 A Example 39 8.5 1.8 A Example 40 17.5 4.8 B Example 41 13.5 1.3 A Example 42 16.8 2.0 A Example 43 23.2 4.2 B Example 44 9.5 0.3 A Example 45 15.3 3.9 B Example 46 20.0 2.6 C Example 47 6.2 0.7 A Example 48 11.7 1.8 A Example 49 12.5 2.7 C Example 50 8.8 1.0 A Example 51 15.2 1.8 A Example 52 26.2 4.5 B Example 53 9.3 0.5 A Example 54 12.5 0.8 A Example 55 14.5 3.3 B Example 56 6.3 0.5 A Example 57 9.7 3.2 B Example 58 13.3 3.8 B Example 59 5.2 0.0 A Example 60 7.7 1.3 A Example 61 10.0 3.2 B Example 62 6.5 1.0 A Example 63 12.8 1.8 A Example 64 15.0 3.3 B Example 65 6.8 0.5 A Example 66 11.7 3.5 B Example 67 18.2 3.8 B Example 68 5.0 0.3 A Example 69 7.7 1.2 A Example 70 15.0 4.0 B Example 71 8.3 1.0 A Example 72 8.5 1.8 A Example 73 17.7 4.5 B Example 74 13.3 1.2 A Example 75 16.5 1.8 A Example 76 23.0 4.3 B Example 77 9.2 0.8 A Example 78 15.2 4.1 B Example 79 20.2 2.6 C Example 80 6.0 0.5 A Example 81 11.3 2.0 A Example 82 12.5 2.7 C Example 83 9.0 1.2 A Example 84 15.2 1.7 A Example 85 26.5 4.7 B Example 86 9.5 0.5 A Example 87 12.5 1.2 A Example 88 14.3 3.2 B Example 89 6.3 0.5 A Example 90 9.5 3.4 B Example 91 13.7 4.0 B Example 92 4.8 0.2 A Example 93 7.8 1.3 A Example 94 10.3 3.5 B Example 95 6.8 0.8 A Example 96 12.8 2.0 A Example 97 14.8 3.5 B Example 98 6.8 0.7 A Example 99 11.7 3.5 B Example 100 18.0 3.8 B Example 101 5.0 0.5 A Example 102 23.0 4.5 B Example 103 20.2 2.9 C Example 104 6.2 0.3 A Example 105 12.8 2.8 C Example 106 6.2 0.7 A Example 107 4.8 0.5 A Example 108 10.3 3.2 B Example 109 8.2 1.3 A Example 110 13.2 1.5 A Example 111 9.2 0.3 A Example 112 26.3 4.3 B Example 113 Synthesis of 9.5 0.5 A Example 114 9.8 3.2 B Example 115 6.5 1.2 A Example 116 7.2 0.8 A Example 117 11.3 3.8 B

As described above, when the granule formulation is formed by using the fast dissolving agent that does not satisfy any one of the instantaneous solubility, the 5 minutes solubility, and the relationship between the instantaneous solubility and the maximum solubility, the effect of the present invention is large because the foreign substance and residual feeling are large. It can be seen that this is not achieved.

[Industrial applicability]

The fast dissolving granules of the present invention are granules having excellent foreign body feeling, residual feeling and refreshing feeling, and dissolve quickly in the oral cavity, have no foreign substances and residual feeling, and provide a fresh feeling. In particular, the formulation of the present invention can achieve the effects of the invention irrespective of the type of active ingredient, it is applicable to a variety of active ingredients. In addition, since the manufacturing process is relatively simple, a high efficiency process can be configured at low cost.

Claims (22)

It is obtained by assembling the fast-soluble carrier and the active ingredient selected from the group consisting of sugars and sugar alcohols, fast dissolving granules, characterized in that it dissolves quickly in the oral cavity during oral administration. The fast dissolving granules according to claim 1, wherein the granules are dissolved within 20 seconds in the oral cavity. According to claim 1 or 2, wherein the sugar and sugar alcohol is xylitol, mannitol, isomalt, sorbitol, maltitol, purified white sugar, lactose, inositol, erythritol, fructose, trehalose, ribitol, arabitol, galactitol, A fast dissolving granule formulation, characterized in that it is selected from the group consisting of lactitol and maltotritol and mixtures thereof. The fast dissolving granules according to claim 3, wherein the fast carrier and the active ingredient are contained in an amount of 40 wt% to 99.995 wt% and 0.005 wt% to 60 wt%, respectively, of the total formulation weight. 5. The fast dissolving granules according to claim 4, wherein the formulation is a final dosage form, and there is no foreign matter and residual feeling even when taken without water. A pharmaceutical product characterized in that the dosage of the fast dissolving granules according to claim 5 is composed of a medicine for single administration in a packaging container. A granule form obtained by assembling an active ingredient and a fast dissolving carrier which dissolves rapidly in the oral cavity, wherein the rapid dissolving granule form is dissolved in the oral cavity within 20 seconds upon oral administration. 8. The fast dissolving granules according to claim 7, wherein the granules have no foreign matter and no residual feeling even when taken without water. The quick-soluble granule formulation according to claim 8, wherein the quick-carrier is a fast-soluble carrier that satisfies the following conditions (1), (2) and (3).
(1) Instantaneous solubility is 30mg / ml or more
(2) 5 minutes solubility is 50 mg / ml or more
(3) Instant solubility is not more than 90% of maximum solubility 10. The fast dissolving granules according to claim 9, wherein the fast solubilizing agent is sugar or sugar alcohol. 11. The fast dissolving granules according to claim 10, wherein the sugar or sugar alcohol has a heat of dissolution of not more than -4.0 dl / g. The sugar and sugar alcohol according to claim 10, wherein the sugar and sugar alcohol are xylitol, mannitol, isomalt, sorbitol, maltitol, refined white sugar, lactose, inositol, erythritol, fructose, trehalose, ribitol, arabitol, galactitol, lactitol and horses. Fast-soluble granules, characterized in that it is selected from the group consisting of totritol and mixtures thereof. 13. The fast dissolving granules according to claim 12, wherein the sugar alcohol is xylitol. According to claim 13, The granules are fast-acting granules, characterized in that even when taken without water there is no foreign matter and residual feeling and there is a refreshing feeling. A pharmaceutical product characterized in that the one-time dosage of the fast-dissolving granules according to claim 9 is composed of a medicine for single administration in a packaging container. A method for producing a granule formulation which dissolves rapidly in the oral cavity during oral administration, comprising the following steps.
(1) mixing an active ingredient and a fast solubilizer selected from sugar and sugar alcohol;
(2) dissolving a pharmaceutically acceptable binder in a purified aqueous solvent to prepare a binder solution;
(3) spraying the binding liquid of step (2) to the mixture of step (1) to form granules; And
(4) mixing the pharmaceutically acceptable additive with the result of step (3) to form a final granule. A method for producing a granule formulation which dissolves rapidly in the oral cavity during oral administration, comprising the following steps.
(1) dissolving or suspending a pharmaceutically acceptable binder and an active ingredient in a solvent to prepare a binder solution;
(2) spraying the binding solution of step (2) to the fast carrier selected from sugar and sugar alcohol to form granules; And
(3) mixing the pharmaceutically acceptable additives with the result of step (2) to form a final granule. 18. The method according to claim 16 or 17, wherein the rapid carrier is a rapid carrier that satisfies the following conditions (1), (2) and (3).
(1) Instantaneous solubility is 30mg / ml or more
(2) 5 minutes solubility is 50 mg / ml or more
(3) Instant solubility is not more than 90% of maximum solubility The method of claim 18, wherein the solute carrier is xylitol, mannitol, isomalt, sorbitol, maltitol, refined white sugar, lactose, inositol, erythritol, fructose, trehalose, ribitol, arabitol, galactitol, lactitol and maltote Production process, characterized in that it is selected from the group consisting of lititol and mixtures thereof. 20. The method according to claim 19, wherein the rapid carrier has a heat of dissolution of -4.0 dl / g or less. 21. The method of claim 20, wherein said fast carrier is xylitol. A granule obtained by granulating by using a sugar or a sugar alcohol that satisfies the following conditions (1), (2) and (3), which is used for the manufacture of a pharmaceutical product.
(1) Instantaneous solubility is 30mg / ml or more
(2) 5 minutes solubility is 50 mg / ml or more
(3) Instant solubility is not more than 90% of maximum solubility